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Abstract
Background: The assessment of bronchodilator-induced change in forced vital capacity (FVC) is
dependent on forced expiratory time (FET) in subjects with airflow limitation. Limited information
is available on the concurrent responses of FVC, forced expiratory volume in six seconds (FEV6),
and FET in the bronchodilation test among patients with obstructive airways disease or in the
general population. The aim of this study was to assess the changes in FEV6, FVC, and FET, and their
relationships in a standardized bronchodilation test in the general population.
Methods: We studied bronchodilation response in a general adult population sample of 628
individuals (260 men, 368 women) with flow-volume spirometry. The largest FVC, the
corresponding FET and the largest FEV6 both at the baseline and after 0.4 mg of inhaled salbutamol
were selected for analysis.
Results: After administration of salbutamol FEV6 decreased on average -13.4 (95% CI -22.3 to -
4.5) ml or -0.2% (-0.4% to 0.0%) from the baseline. The 95th percentile of change in FEV6 was 169.1
ml and 5.0%. FVC decreased on average -42.8 (-52.4 to -33.3) ml or -1.0% (-1.2% to -0.7%).
Concurrently FET changed on average -0.2 (-0.4 to 0.0) seconds or 0.4% (-1.4% to 2.3%). There
were four subjects with an increase of FVC over 12% and only one of these was associated with
prolonged FET after salbutamol. Changes in FEV6 and FVC were more frequently positive in
subjects with reduced FEV1/FVC in baseline spirometry.
Conclusion:  In general adult population, both FEV6 and FVC tended to decrease, but FET
remained almost unchanged, in the bronchodilation test. However, those subjects with signs of
airflow limitation at the baseline showed frequently some increase of FEV6 and FVC in the
bronchodilation test without change in FET. We suggest that FEV6 could be used in assessment of
bronchodilation response in lieu of FVC removing the need for regulation of FET during
bronchodilation testing.
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Introduction
In recent years forced expiratory volume in six seconds
(FEV6) has evolved as a novel parameter in flow-volume
spirometry that has been suggested to replace forced vital
capacity (FVC) for some clinical applications [1-4]. A
practical benefit of using FEV6 would be easier perform-
ance by patients because maximal end-expiration can be
avoided. This measure could especially lend itself for use
in the primary care setting [1]. Reference values and data
on reliability and utility in the diagnosis of obstructive
and restrictive lung diseases are emerging for FEV6 [2-9].
Bronchodilation induced by pharmacological agents is an
important feature of asthma, whereas chronic obstructive
pulmonary disease (COPD) is characterized by chronic
airflow limitation that is not fully reversible [10]. In
COPD, bronchodilation response may be reflected as
increase of FVC, as an indicator of relief of air trapping
[11,12]. The FVC manoeuvre is technically demanding,
significantly affected by expiratory time in subjects with
airflow limitation, and sensitive to the impact of tiring
[13].
The joint American Thoracic Society (ATS) and European
Respiratory Society (ERS) Task Force on Standardisation
of Lung Function Testing recommended in 2005 that a
12% and 200 ml improvement in either FEV1 or FVC from
baseline would be considered a significant bronchodila-
tion response [14]. Recently we have shown that FEV1
response to bronchodilation by around 9% from the base-
line in an adult urban population is significant [15]. If
bronchodilation response is observed only in FVC, the
concurrent change in forced expiratory time (FET) should
be evaluated [14]. Based on the observed intra-session
variability of FET in the general population, we have sug-
gested that 3 seconds would constitute a significant
change [16]. In subjects with airflow limitation the intra-
session repeatability of FEV6 was at least equal to the
repeatability of FVC [16]. FEV6 is the least variable of the
FEVx [17]. Both FEV3  and FEV6  have been shown to
increase significantly when the increase in FVC was not
caused by longer exhalation time [18]. Standardisation of
FET during bronchodilation testing is problematic. Since
FEV6 would offer better repeatability and an unequivocal
end-of-test measure, it would be interesting to assess FEV6
as a surrogate measure of FVC response in the bronchodi-
lation test.
The aim of this study was to evaluate the concurrent
changes in FEV6, FVC, and FET in a standardized bron-
chodilation test and their association with airflow limita-
tion in a general adult population sample using flow-
volume spirometry. Furthermore, the role of FEV6 as a sur-
rogate of FVC in the bronchodilation test was evaluated.
Materials and methods
Subjects
In 1995 the original sample of 8000 adults aged 20–69
years was randomly selected from the Finnish Population
Registre Center to represent the adult population of Hel-
sinki, Finland. Randomization was stratified by gender
and 10-year age cohorts. In phase I a postal questionnaire
study was completed, with 6062 responders. In 2000 a
further random sample of 1200 subjects were sampled
from the original postal questionnaire responders to a
subsequent clinical study. During 2000–2003 a total of
643 subjects participated in phase II of the FinEsS-Hel-
sinki study. The study protocol has been reported in pre-
vious articles [15,16,19].
In this study, 628 acceptable spirometric measurements
(260 for men, 368 for women) with bronchodilation test-
ing and a structured interview were completed. Study sub-
jects were interviewed using a structured questionnaire to
obtain information about general health, respiratory ill-
nesses, medications and environmental exposures. The
Finnish FinEsS structured interview has been developed
from the OLIN questionnaire [20,21].
The study was conducted according to the Helsinki Decla-
ration and approved by the Ethics Committee of the
Department of Medicine of Helsinki University Central
Hospital. All participants gave informed consent.
Measurements
Spirometry procedures were based on the 1994 recom-
mendation of the American Thoracic Society [22], with
the exception of repeatability criteria that were based on
modified ERS criteria [23]. The two largest FEV1 and FVC
were required to be within 150 ml or 5% of the respective
volume, whichever was greater, and the two largest peak
expiratory flows (PEF) were required to be within 10%.
Spirometry was completed with a flow-volume spirome-
try device (VMax 20c, Sensor Medics, Yorba Linda, CA,
USA) with the patient seated. Each subject performed
three to eight forced expiratory manoeuvres and inspira-
tory spirograms were recorded in conjunction with expir-
atory spirograms whenever feasible. In the
bronchodilation test the subjects inhaled 0.4 mg of salb-
utamol aerosol (Ventoline 0.2 mg, GlaxoSmithKline, Lon-
don, UK) through a spacer device (Volumatic,
GlaxoSmithKline, London, UK) on two separate doses
and spirometry was repeated after 15 minutes rest.
Spirometry was evaluated using the current Finnish refer-
ence values, which do not yet contain reference values for
FEV6 [24]. The detailed spirometry procedure has been
published previously [15,16].Respiratory Research 2009, 10:71 http://respiratory-research.com/content/10/1/71
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The spirometry variables evaluated in this study were FVC,
FEV6 and FET. The largest FEV6 and FVC from the accepta-
ble pre- and post-bronchodilation curves, and the FET
measured from the curve with the largest FVC were
selected for analysis. The FET defined and recorded by the
spirometer software was used (Vision Software 05-2A,
Vmax System, Sensor Medics, Yorba Linda, CA, USA). The
beginning point of measurement is the back extrapolated
time zero [14,25] and the end-point at the beginning of
the end-expiratory plateau. In cases where the total exha-
lation time recorded by the spirometer was under six sec-
onds, the FVC was used in lieu of FEV6. The difference
between baseline spirometry and post-bronchodilator
spirometry was assessed using both absolute change and
change relative to baseline spirometry.
The smoking history was evaluated from the structured
interview and subjects were categorized into never-smok-
ers, former smokers and current smokers in addition to
calculating smoking pack-years for the ever-smokers.
Former smokers were required to have stopped smoking
at least 12 months prior to the study. Previously pub-
lished criteria based on the structured interview were used
to define a subgroup of healthy asymptomatic non-smok-
ers [15,20] to assess the upper limit of normal. The
anthropometric parameters analysed were gender, age,
height, weight, and body mass index (BMI, kg/m2). The
descriptive statistics of the study population including
baseline spirometric results and smoking history are out-
lined in Table 1.
Analysis
Statistical analyses were performed with SPSS for Win-
dows (version 15.01; SPSS, Chicago, IL, USA). Distribu-
tion of parameters was assessed using scatter graphs and
normality was assessed with the Kolmogorov-Smirnov
test for normality. Pearson correlation coefficient (r) was
used to assess the correlation of changes in FVC and FEV6
with FET. The intra-class correlation coefficient was used
to assess the agreement between change in FVC and FEV6
using a one-way random effects model [26,27]. The intra-
class correlation coefficient produces measures of consist-
ency or agreement of values within cases. Analysis of var-
iance (ANOVA) was used for categorical comparisons. The
method described by Bland & Altman [28] was modified
to demonstrate dependence of change in FVC and FET of
their respective average values [29]. P-values less than
0.05 were considered statistically significant for all other
analyses, except for correlations, for which a p-value less
than 0.01 was regarded significant. All analyses were two-
sided unless otherwise indicated.
Results
Changes in FVC and FEV6 in bronchodilation test were
normally distributed. The concurrent changes in FEV6,
FVC and FET in the bronchodilation test are outlined in
Table 2. FEV6 decreased statistically significantly more in
women both in absolute and in relative terms, whereas
the gender difference was only significant in relative
change in FVC. Change of FVC and FET in relation to their
respective average values are shown in Figure 1 in a mod-
Table 1: Anthropometric and baseline spirometric statistics of the study population
men (n = 260) women (n = 368)
mean (SD) 95% CI range mean (SD) 95% CI range
age [yrs] 48.6 (12.7) 47.0–50.1 26.3–74.2 49.5 (13.2) 48.2–50.9 25.7–74.4
height [m] 1.78 (0.07) 1.77–1.79 1.62–1.98 1.64 (0.06) 1.63–1.64 1.46–1.83
weight [kg] 83.9 (14.1) 82.2–85.6 52.4–139.0 68.8 (13.7) 67.4–70.2 44.0–133.0
BMI [kg/m2] 26.5 (4.3) 26.0–27.0 17.1–44.9 25.7 (5.1) 25.2–26.2 16.9–53.3
baseline FVC [l] 5.075 (0.911) 4.964–5.187 2.182–8.033 3.549 (0.660) 3.482–3.617 2.013–5.388
baseline FVC % of reference* 98.1 (12.3) 96.6–99.6 50.8–131.2 99.5 (12.5) 98.2–100.7 71.9–144.6
baseline FEV1 [l] 3.897 (0.832) 3.795–3.999 1.016–5.895 2.784 (0.591) 2.724–2.845 0.992–4.495
baseline FEV1 % of reference* 92.9 (14.9) 91.0–94.7 29.3–128.7 94.7 (13.1) 93.3–96.0 40.6–132.8
baseline FEV6 [l]** 4.888 (0.937) 4.774–5.002 2.14–7.75 3.437 (0.675) 3.368–3.506 1.84–5.31
baseline FET [s] ± 11.5 (4.3) 11.0–12.1 1.6–37.0 10.5 (4.5) 10.0–10.9 1.7–36.8
baseline FEV1/FVC [%] 76.5 (7.8) 75.5–77.5 34.8–96.3 78.3 (7.0) 77.6–79.0 44.7–92.9
baseline FEV1/FVC % of reference* 94.5 (9.6) 93.4–95.7 42.6–121.2 95.3 (8.0) 94.5–96.1 55.1–114.9
pack-years
mean (SD)
range pack-years
mean (SD)
range
non-smokers† n = 112 n.a. n.a. n = 226 n.a. n.a.
former smokers n = 59 23.6 (16.9) 5.5–82.5 n = 49 18.0 (13.7) 1.2–66.0
current smokers n = 89 26.2 (22.0) 0.4–95.0 n = 93 19.1 (16.0) 0.6–86.0
BMI = body mass index; FVC = forced vital capacity; FEV1 = forced expiratory volume in one second; FEV6 = forced expiratory volume in six 
seconds; FET = forced expiratory time; n.a. = not applicable
* predicted values from [24]
** maximum value of acceptable curves
± value corresponding to largest FVC measurement
† including former smokers smoking under 5 pack-years and smoking cessation over 5 years previouslyRespiratory Research 2009, 10:71 http://respiratory-research.com/content/10/1/71
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ified Bland-Altman plot. At higher FVC there were less
bronchodilation changes, but at higher FET more frequent
changes associated with both underlying airflow limita-
tion and poorer repeatability of FET in comparison to
FVC. In the bronchodilation test 23.1% of men and
33.2% of women had a decrease of FVC greater than 2.5%
from the baseline. The mean change in FVC was -42.8
(95% CI -52.4 to -33.3) ml or -1.0% (-1.2% to -0.7%). The
upper 95th percentile for change in FVC was 137.0 ml and
4.0%. The mean change in FET was -0.2 (-0.4–0.0) sec-
onds or 0.4% (-1.4%–2.3%), with a 95th percentile of 3.4
seconds or 44.0%.
FEV6 tended to decrease during bronchodilation test, but
the mean reduction was less marked than in FVC (mean
change -13.4 (-22.3 to -4.5) ml or -0.2% (-0.4%–0.0%)).
The 95th percentile for change in FEV6 was 169.1 ml and
5.0%. The individual concurrent changes in FEV6 and FVC
are demonstrated in Figure 2. The intra-class correlation
coefficient (ICC) for the concurrent absolute change in
FEV6 and FVC was 0.84 (0.82–0.87) and for the relative
change 0.86 (0.83–0.88). The agreement between changes
in FEV6  and FVC was better in subjects with airways
obstruction (FEV1/FVC post-bronchodilator < LLN); ICC
for the relative change in subjects with obstruction was
0.91 (0.84–0.95) and in those who were non-obstructed
0.80 (0.77–0.83). Age, height, weight or BMI did not cor-
relate significantly with changes in FVC, FEV6 or FET dur-
ing the bronchodilation test.
There were four subjects with the increase of FVC from the
baseline at least 12% and 200 ml, yielding a population
prevalence of 0.6% for a significant improvement of FVC
in the bronchodilation test. Using the same threshold val-
ues six subjects showed a significant change of FEV6. The
changes in FVC, FEV6, FEV1 and FET of these subjects are
individually shown in Table 3. One subject had a signifi-
cant increase in FVC, but an insignificant increase in FEV6;
for her the increase of FVC was associated with an increase
of FET by 8 seconds and 71% relative to the baseline FET.
Three subjects had a significant increase in FEV6 but a
smaller increase in FVC, which were associated to shorter
FET in post-bronchodilator spirometry.
The relationship of individual changes of FVC and the dif-
ference between changes in FEV6 and FVC in bronchodila-
tion test, to baseline FEV1/FVC is demonstrated in Figure
3. Increase of FVC in the bronchodilation test associated
inversely with FEV1/FVC ratio and FEV1. The changes in
flow-volume spirometry variables stratified by FEV1/FVC
ratio at the baseline below or above lower limit of normal
(LLN) are shown in Table 4. In subjects with airflow limi-
tation the changes in FEV6 and FVC were on the average
+2.4% and +0.8%, respectively. In subjects with no air-
Bland & Altman graphs depicting: a) individual changes in forced vital capacity (FVC) in relation to average FVC, and b) individ- ual changes in forced expiratory time (FET) in relation to average FET, in a bronchodilation test with salbutamol aerosol 0.4 mg  in the general adult population (n = 628) Figure 1
Bland & Altman graphs depicting: a) individual changes in forced vital capacity (FVC) in relation to average 
FVC, and b) individual changes in forced expiratory time (FET) in relation to average FET, in a bronchodila-
tion test with salbutamol aerosol 0.4 mg in the general adult population (n = 628). The dotted lines indicate the 2 
SD limits from the respective mean value. Larger bronchodilation responses in FVC were seen in subjects with lower FVC and 
larger variation in FET with prolonged FET, which was associated to more severe obstruction.Respiratory Research 2009, 10:71 http://respiratory-research.com/content/10/1/71
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flow limitation the corresponding values were -0.7% and
-1.3%. Conversely, there was no significant difference in
FET between the subjects with or without airflow limita-
tion at the baseline.
For healthy asymptomatic non-smokers (n = 219), the
95th percentile of change in FEV6 was 112.0 ml and 3.4%,
change in FVC 92.0 ml and 2.5%, and change in FET 3.7
seconds and 50.0%.
Discussion
The present study indicates that increase of FVC in
response to inhaled salbutamol in the bronchodilation
test in a general population sample is infrequent and is
only rarely associated to increased expiratory time.
Amongst subjects with baseline airflow limitation, FEV6
response differentiated those individuals by whom
increase of FVC was caused by longer exhalation time.
This is important, because it implies that the use of FEV6
would help to remove the need for standardization of
exhalation time during standard bronchodilation testing.
Decrease of FVC during the bronchodilation test was
more frequent than previously reported, especially in
healthy subjects. Therefore, the limit of significant
increase of FVC might be lower than previously thought.
However, the limits of any significant change are depend-
ent of the inherent variability of the measures, like FVC,
FEV6 and FET.
Bronchodilation response in flow-volume spirometry is
primarily assessed with FEV1, but a significant response
can also be seen in other measures, such as FVC [11-
13,18,30-32]. It has been hypothesized that in patients
with chronic airflow limitation combined with hyperin-
flation the potential increase of expiratory airflow due to
bronchodilation may be attenuated in small airways due
to airway-to-parenchymal interdependence [12]. The
degree of obstruction in COPD has been found to modify
the spirometric response to bronchodilation; FEV1
response shown to dominate in mild obstruction (GOLD
Stage I-II) and FVC response in severe obstruction (GOLD
III-IV) [11]. Also in our material from general population
FVC response to bronchodilator increased as the post-
bronchodilator FEV1/FVC ratio decreased as shown in Fig-
ure 3. However, especially in subjects with airflow limita-
tion FVC has been found to depend on forced expiratory
time; longer exhalations potentially created higher FVC
values not necessarily due to actual bronchodilation [13].
At the present, FET is not routinely given in the reports of
flow-volume spirometry and there is limited information
on the concurrent changes of FET and FVC. It has been
suggested, but not proved, that an increase in FET during
bronchodilation testing in severely obstructed individuals
could reflect bronchodilation in small airways [31,33].
Since a positive response in FVC is most often seen in
more severe COPD in a bronchodilation test, a large part
of the bronchodilation studies assessing changes in lung
volumes have been conducted in groups of patients with
obstructive pulmonary diseases [12,14,18,30-32]. Bron-
chodilating medication, its dose and mode of delivery
have varied making comparisons difficult. Most studies
with large number of individuals have been conducted
based on patient databases, where the exclusion of
untreated asthmatics is nearly impossible [31].
Differing views have been voiced on the interpretation of
FVC response. In patients with marked hyperinflation,
bronchodilation response has been demonstrated to
occur in inspiratory capacity (IC) and residual volume
(RV) with better correlation to symptom relief than with
other spirometric variables [31,32]. Changes in vital
capacity (VC) might in some individuals better correlate
with symptomatic relief from bronchodilating medica-
tion and FVC can underestimate this volume response
[34]. However, when assessing changes measured with
flow-volume spirometry, FEV6 would offer a measure that
is not influenced by as many pathophysiological factors as
Table 2: Concurrent changes in forced expiratory volume in one (FEV1) and six (FEV6) seconds, forced vital capacity (FVC) and forced 
expiratory time (FET) in the bronchodilation test in general population
men (n = 260) women (n = 368)
mean (SD) 95% CI 95th percentile mean (SD) 95% CI 95th percentile gender difference
(p value)
change of FEV1 [ml] 107.4 (130.6) 91.4 – 123.3 335.3 55.9 (86.2) 47.1 – 64.8 214.5 <0.001
change of FEV1 % from baseline 3.0 (4.3) 2.5 – 3.5 8.6 2.2 (3.7) 1.8 – 2.6 8.4 0.009
change of FEV6 [ml] -2.1 (137.7) -18.9 – 14.8 195.8 -21.4 (93.5) -31.0 – -11.8 144.9 0.036
change of FEV6 % from baseline 0.1 (3.5) -0.3 – 0.6 4.8 -0.5 (3.1) -0.8 – -0.2 5.1 0.023
change of FVC [ml] -35.6 (147.6) -53.6 – -17.6 170.2 -48.1 (100.9) -58.4 – -37.8 132.2 n.s.
change of FVC % from baseline -0.6 (3.4) -1.0 – -0.2 3.6 -1.2 (3.2) -1.6 – -0.9 4.4 0.016
change of FET [s] -0.1 (2.6) -0.5 – 0.2 3.2 -0.3 (2.7) -0.5 – 0.0 3.7 n.s.
change of FET % from baseline -0.6 (21.2) -3.2 – 2.0 34.7 1.2 (25.6) -1.4 – 3.8 48.6 n.s.
FEVt = forced expiratory volume in t second(s), FVC = forced vital capacity; FET = forced expiratory time; CI = confidence interval; n.s. = not 
significantRespiratory Research 2009, 10:71 http://respiratory-research.com/content/10/1/71
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FVC. Increase in FEV6 may partially reflect flow changes
also in small airways. Variables regarded to represent
small airways (MEF50, MMEF) have greater inter- and
intra-session variability than FEV6 [35,36] and are affected
by concurrent changes in FVC. It is theoretically possible
that in subjects with marked peripheral airways obstruc-
tion prolongation of FET after bronchodilation could
imply decreased hyperinflation.
The frequent negative changes in FVC during bronchodi-
lation test have to date been largely neglected. However, it
greatly affects the distribution of values and the assess-
ment of upper limit of normal change. We found 23% of
men and 33% of women to have greater than 2.5% reduc-
tion in FVC in the bronchodilation test. One reason for
reduction of FVC after the bronchodilator in healthy sub-
jects could be the increased collapsibility of the airways as
a result of the reduced airway smooth muscle tone with
β2-agonists [37]. On the contrary, those subjects with
markedly reduced FEV1/FVC ratio indicating bronchial
obstruction showed increased FVC after bronchodilation
in our population study (Figure 3, Table 4). In this popu-
lation, the upper 95th percentiles for change in FEV6 and
FVC were around 5% and 4% from baseline, respectively.
The corresponding values for the subgroup of healthy
asymptomatic non-smokers were 3.4% and 2.5%.
When considering significant changes in bronchodilation
testing, it is necessary to evaluate also the inherent meas-
urement variability. In a large patient sample, the intra-
session repeatability of FVC has been shown to have a 95th
percentile of 7.0% or 180 ml [38] although that study
didn't control concurrent variations in FET either. In our
earlier report from the present population sample the 95th
percentiles of the intra-session repeatability of FEV6 and
FVC were 3.3% or 117 ml and 3.2% or 119 ml, respec-
tively [16]. Concurrently FET varied on average -0.0 (2.0)
seconds with a 95th percentile of 2.7 seconds. Earlier, Pen-
nock and coworkers have concluded that the within-day
repeatability of FVC is 6.7% and FEV1 8.1% in obstructive
subjects [36]. Although our results imply that an increase
in FVC due to bronchodilation is statistically significant at
a lower level than given in the current standards [14], the
limit for significant change cannot be lower than the
repeatability of the measurement.
In our study, very few positive FEV6 or FVC bronchodila-
tion responses were detected in the unselected population
sample, which limits the possibilities of further analysis in
this study. This can partially be caused by the fact that reg-
ular medication was not discontinued for the study and
hence subjects with asthma were on appropriate treat-
ment. Since the number of subjects with positive
responses was this limited in the population, concurrent
changes in FEV6, FVC, and FET should be further evalu-
ated in subjects with varying degrees of obstruction. How-
ever, it is clear from this unselected population study that
FVC tends to decrease in the healthy subjects and thus
positive changes – most likely in those with airflow
obstruction – are significant at a lower level than previ-
ously thought. No differences were detected between dif-
ferent age-groups, but the negative changes were slightly
more common in women. However, men had more air-
flow limitation, which was associated with more frequent
positive changes in FEV6 and FVC during the bronchodila-
tion test.
FEV6 performed in this study comparably with FVC, sug-
gesting that it could be considered a surrogate for FVC in
the bronchodilation test. FVC might underestimate
changes in vital capacity (VC) in subjects with severe air-
flow limitation and air trapping, which has been sug-
gested to partially account for their subjective benefit of
bronchodilating medication in clinical practice [34]. In
subjects with airflow limitation, change in FEV6 was sig-
nificant in three subjects that had shorter exhalations in
post-bronchodilation spirometry, which resulted in
changes in FVC remaining below significant change limits
Individual changes of forced vital capacity (FVC) and forced  expiratory volume in six seconds (FEV6) after bronchodila- tion in the general adult population (n = 628) Figure 2
Individual changes of forced vital capacity (FVC) and 
forced expiratory volume in six seconds (FEV6) after 
bronchodilation in the general adult population (n = 
628). The dotted lines represent the significant change limit 
of 12% from the baseline [14] for FVC. All subjects with a 
change over 12% also fulfilled the absolute change criterion 
of 200 ml. The thick arrow highlights one subject with pro-
longed post-bronchodilation FET resulting in increase of FVC 
in the absence of significant change in FEV6. The small arrows 
show subjects with significantly improved FEV6 in the absence 
of increase in FVC, caused by shorter exhalations in post-
bronchodilation spirometry. ICC = intra-class correlation.Respiratory Research 2009, 10:71 http://respiratory-research.com/content/10/1/71
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(Table 3). We chose to replace FEV6 with FVC when FET
was under 6 seconds, because the exclusion of these sub-
jects would have created a selection bias. In subjects with
FET < 6 seconds, most often healthy young adults, FVC is
not dependent on FET [39]. The intra-class correlation
coefficient showed good agreement between changes in
FEV6 and FVC especially in subjects with airflow limita-
tion in spirometry. Earlier Girard & Light have also shown
that timed expiratory flows (FEV3 and FEV6) generally
increase if the increase in FVC is not being caused by
longer FET [13]. Previously it has been reported that FEV6
has the least within-session variability of the FEVx values
[17] when exhalation times are over 10 seconds. It is sug-
gested that the use of FEV6 would preclude the need to
standardize FET and could act as a measure of bronchodi-
lation especially in the primary care. The current standard
Table 3: Data of subjects with significant changes in forced expiratory volume in six seconds (FEV6) or forced vital capacity (FVC) in 
the bronchodilation test
age gender FEV1/FVC post FEV1
post
smoking status history of OAD change in FVC change in FEV6 change in FET change in FEV1
[yrs] [%] [%*] [pack-years] ml % ml % s % ml %
52.9 m 48.9% 62.1% current smoker 
22.2
asthma 1183 32.8 979 34,1 0.3 1.5 573 32.4
50.5 w 55.5% 59.7% current smoker 
33.0
no dg
no med
350 11.6 424 15.9 -1.2 -10.1 381 25.5
67.8 m 44.7% 51.4% former smoker 
35.0
COPD 557 16.0 446 15.2 2.9 22.1 321 21.6
47.5 w 50.0% 51.9% current smoker 
52.2
asthma 350 12.5 336 15.1 -1.7 -9.2 246 18.5
63.0 m 38.7% 46.9% current smoker 
84.0
no dg asthma 
med
353 9.5 418 14.2 -1.3 -7.8 241 18.1
52.6 w 78.4 79.3 non-smoker
0.0
asthma 240 8.9 329 12.9 -4.5 -34.5 364 18.8
52.4 w 43.1% 45.0% former smoker 
14.0
asthma 378 17.4 107 5.8 8.0 70.7 109 11.0
FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; OAD = obstructive airways disease; FEV6 = forced expiratory volume 
in six seconds; FET = forced expiratory time; dg = diagnosis; med = medication.
* of predicted values from [24]
The relationship of a) individual changes in forced vital capacity (FVC) after bronchodilation, and b) the difference between the  individual changes in forced expiratory volume in six seconds (FEV6) and FVC, to the ratio of forced expiratory volume in one  second (FEV1) to FVC at the baseline in general adult population (n = 628) Figure 3
The relationship of a) individual changes in forced vital capacity (FVC) after bronchodilation, and b) the differ-
ence between the individual changes in forced expiratory volume in six seconds (FEV6) and FVC, to the ratio of 
forced expiratory volume in one second (FEV1) to FVC at the baseline in general adult population (n = 628). 
The dotted line indicates the FEV1/FVC limit for airflow obstruction (0.7). In subjects with airflow obstruction, positive FVC 
bronchodilation response was more common and the difference between FVC and FEV6 responses tended to be larger.Respiratory Research 2009, 10:71 http://respiratory-research.com/content/10/1/71
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states that FET should be analysed from those curves
where the sum of FVC and FEV1 is the greatest [25]. Since
FET varies within test session more than FVC and FEV1
[16], we suggest that in the bronchodilation test FET
should be analysed from those curves with the largest FVC
values. FEV6 is more repeatable than FVC also in subjects
with reduced FEV1/FVC [15]. Earlier it has been disputed
that the use of FEV6 could more easily misclassify subjects
with borderline obstruction [4,5,7,8,40], but since posi-
tive changes in FVC in the bronchodilation test are more
likely to occur in more severe airflow limitation, this
should not become a problem for the use of FEV6 as a
measure of bronchodilation in lieu of FVC.
In conclusion, we found that in a general population sam-
ple, positive FVC and FEV6 response to bronchodilation in
flow-volume spirometry was infrequent occurring almost
solely in subjects with bronchial airflow limitation. In
subjects with normal FEV1/FVC ratio both FVC and FEV6,
on the average, decreased. We suggest that FEV6 could be
used in assessment of bronchodilation response in flow-
volume spirometry instead of FVC; significant increase of
FEV6 would seem to be around 6%. By using FEV6 for
assessment of bronchodilator effect instead of FVC would
remove the need for regulation of forced exhalation time
during a bronchodilation test.
Abbreviations
ATS: American Thoracic Society; ANOVA: analysis of vari-
ance; BMI: body mass index; CI: confidence interval;
COPD: chronic obstructive pulmonary disease; ERS: Euro-
pean Respiratory Society; FET: forced expiratory time;
FEVx: forced expiratory volume in × seconds; FVC: forced
vital capacity; GOLD: Global Initiative for Chronic
Obstructive Lung Disease; IC: Inspiratory capacity; ICC:
intra-class correlation coefficient; LLN: lower limit of nor-
mal; MEF50: maximal instantaneous forced expiratory
flow where 50% of FVC remains to be expired; MMEF:
maximum mid-expiratory flow; OLIN: Obstructive Lung
Disease in Northern Sweden Study; PEF: peak expiratory
flow; RV: residual volume.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AK has conducted the data processing and statistical anal-
yses with consultative help from SS. AK has mainly
drafted the text and illustrations of the article, with edito-
rial advice from BL, AL and AS, who also have contributed
to the text. All authors have read and approved the final
manuscript.
Acknowledgements
The FinEsS-Helsinki study has been funded from Helsinki University Central 
Hospital special governmental subsidy TYH 1235, TYH 2303, and TYH 
4251. A.K. was funded by grants from Ida Montin Foundation, The Finnish 
Lung Foundation (HELI), Foundation of the Finnish Anti-Tuberculosis Asso-
ciation and Helsinki University Central Hospital special governmental sub-
sidy research grant.
References
1. Ferguson GT, Enright PL, Buist AS, Higgins MW: National Lung
Health Education Program (NLHEP). Office spirometry for
lung health assessment in adults: a consensus statement
from the National Lung Health Education Program.  Chest
2000, 117:1146-1161.
2. Swanney MP, Jensen RL, Crichton DA, Beckert LE, Cardno LA, Crapo
RO: FEV6 is an Acceptable Surrogate for FVC in the Spiro-
metric Diagnosis of Airway Obstruction and Restriction.  Am
J Respir Crit Care Med 2000, 162:917-919.
3. Enright PL, Connett JE, Bailey WC: The FEV1/FEV6 predicts lung
function decline in adult smokers.  Respiratory Medicine 2002,
96:444-449.
4. Akpinar-Elci M, Fedan KB, Enright PL: FEV6 as a surrogate for
FVC in detecting airways obstruction and restriction in the
workplace.  Eur Respir J 2006, 27:374-7.
5. Hankinson JL, Crapo RO, Jensen RL: Spirometric Reference Val-
ues for the 6-s FVC Maneuver.  Chest 2003, 124:1805-1811.
6. Garcia-Rio F, Pino JM, Dorgham A, Alonso A, Villamor J: Spiromet-
ric reference equations for European females and males
aged 65–85 yrs.  Eur Respir J 2004, 24:397-405.
Table 4: Change in flow-volume spirometry variables in subjects with and without airflow limitation at the baseline in the population 
sample
FEV1/FVC ≥ LLN*
(n = 537)
mean (SD)
FEV1/FVC < LLN*
(n = 91)
mean (SD)
p value
change of FEV1 (ml) 66.2 (99.9) 142.6 (139.1) p < 0.001
(% from baseline) 1.9 (2.9) 6.2 (6.4) p < 0.001
change of FEV6 (ml) -27.3 (98.0) 68.8 (160.1) p < 0.001
(% from baseline) -0.7 (2.5) 2.4 (5.4) p < 0.001
change of FVC (ml) -52.8 (103.2) 15.4 (192.3) p < 0.001
(% from baseline) -1.3 (2.6) 0.8 (5.6) p < 0.001
change of FET (s) -0.2 (2.5) -0.4 (3.5) p = 0.563
(% from baseline) 0.8 (24.1) -1.6 (22.3) p = 0.370
FET = forced expiratory time; FEV1 = forced expiratory volume in one second; FEV6 = forced expiratory volume in six seconds; FVC = forced vital 
capacity; LLN = lower limit of normal
* predicted values from [24]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Respiratory Research 2009, 10:71 http://respiratory-research.com/content/10/1/71
Page 9 of 9
(page number not for citation purposes)
7. Hansen JE, Sun X-G, Wasserman K: Should forced expiratory vol-
ume in six seconds replace forced vital capacity to detect air-
way obstruction?  Eur Respir J 2006, 27:1244-1250.
8. Vandevoorde J, Verbanck S, Schuermans D, Kartounian J, Vincken W:
FEV1/FEV6 and FEV6 as an Alternative for FEV1/FVC and
FVC in the Spirometric Detection of Airway Obstruction
and Restriction.  Chest 2005, 127:1560-1564.
9. Vandevoorde J, Verbanck S, Schuermans D, Broekaert L, Devroey D,
Kartounian J, Vincken W: Forced vital capacity and forced expir-
atory volume in six seconds as predictors of reduced total
lung capacity.  Eur Respir J 2008, 31:391-395.
10. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi
Y, Jenkins C, Rodriquez-Roisin R, van Weel C, Zielinski J: Global
Strategy for the Diagnosis, Management, and Prevention of
Chronic Obstructive Pulmonary Disease. GOLD Executive
Summary.  Am J Respir Crit Care Med 2007, 176:532-555.
11. Schermer T, Heijdra Y, Zadel S, Bemt L van den, Boonman-de Winter
L, Dekhuijzen R, Smeele I: Flow and volume responses after rou-
tine salbutamol reversibility testing in mild to very severe
COPD.  Respir Med 2007, 101:1355-1362.
12. Cerveri I, Pellegrino R, Dore R, Corsico A, Fulgoni P, Woestijne KP
van de, Brusasco V: Mechanisms for isolated volume response
to a bronchodilator in patients with COPD.  J Appl Physiol 2000,
88:1989-1995.
13. Girard WM, Light RW: Should the FVC be considered in evalu-
ating response to bronchodilator?  Chest 1983, 84:87-89.
14. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R,
Coates A, Grinten CPM van der, Gustafsson P, Hankinson J, Jensen R,
Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen
OF, Wanger J: Interpretative strategies for lung function tests.
Eur Respir J 2005, 26:948-968.
15. Kainu A, Lindqvist A, Sarna S, Lundbäck B, Sovijärvi A: FEV1
response to bronchodilation in an adult urban population
and in healthy adults.  Chest 2008, 134:387-393.
16. Kainu A, Lindqvist A, Sarna S, Sovijärvi A: Intra-session repeatabil-
ity of FET and FEV6 in the general population.  Clin Phys Funct
Imag 2008, 28:196-201.
17. Jensen RL, Crapo RO, Enright P, Others From the Family Heart Study:
A Statistical Rationale for the Use of Forced Expiratory Vol-
ume in 6s.  Chest 2006, 130:1650-1656.
18. Light RW, Conrad SA, George RB: The one best test for evaluat-
ing the effects of bronchodilator therapy.  Chest 1977,
72:512-516.
19. Pallasaho P, Rönmark E, Haahtela T, Sovijärvi ARA, Lundbäck B:
Degree and clinical relevance of sensitization to common
allergens among adults: a population study in Helsinki, Fin-
land.  Clin Exp All 2006, 36:503-509.
20. Kainu A: Spirometric studies on the adult general population
of Helsinki-bronchodilation responses, determinants, and
intrasession repeatability of FEV1, FEV6, FVC, and forced
expiratory time A report from the FinEsS-Helsinki II study.
University of Helsinki Thesis 2008:84-98.
21. Lundbäck B: Asthma, chronic bronchitis and respiratory
symptoms: prevalence and important determinants. The
Obstructive Lung Disease in Northern Sweden Study I.  Umeå
University Medical Dissertations 1993, 387:1-118. Appendix: i-xii
22. American Thoracic Society: Standardisation of Spirometry.
1994 Update.  Am J Respir Crit Care Med 1995, 152:1107-1136.
23. Quanjer Ph H, Tammeling GJ, Coters JE, Pedersen OF, Peslin R, Yer-
nault J-C: Lung Volumes and Forced Ventilatory Flows.
Report Working Party. Official Statement of the European
Respiratory Society.  Eur Respir J 1993, 6(Suppl 16):5-40.
24. Viljanen AA, Halttunen PK, Kreus K-E, Viljanen BC: Spirometric
studies in non-smoking, healthy adults.  Scand J Clin Lab Invest
1982, 42:5-20.
25. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A,
Crapo R, Enright P, Grinten CPM van der, Gustafsson P, Jensen R,
Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pel-
legrino R, Viegi G, Wanger J: Series "ATS/ERS Task Force:
Standardisation of Lung Function Testing". Standardisation
of spirometry.  Eur Respir J 2005, 26:319-338.
26. Shrout PE, Fleiss JL: Intraclass correlations: Uses in assessing
rater reliability.  Psychological Bulletin 1979, 86:420-428.
27. McGraw KO, Wong SP: Forming inferences about some intra-
class correlation coefficients.  Psychological Methods 1996,
1:30-46.
28. Bland JM, Altman DG: Statistical methods for assessing agree-
ment between two methods of clinical measurement.  Lancet
1986, i:307-310.
29. Chinn S: Repeatability and method comparison. Statistics in
respiratory medicine.  Thorax 1991, 46:454-456.
30. Ramsdell JW, Tisi GM: Determination of bronchodilation in the
clinical pulmonary function laboratory. Role of changes in
static lung volumes.  Chest 1979, 76:622-628.
31. Newton MF, O'Donnell DE, Forkert L: Response of lung volumes
to inhaled salbutamol in a large population of patients with
severe hyperinflation.  Chest 2002, 121:1042-1050.
32. Pellegrino R, Rodarte JR, Brusasco V: Assessing the reversibility
of airway obstruction.  Chest 1998, 114:1607-1612.
33. Tsai AG, Christie JD, Gaughan CA, Palma WR Jr, Margolis ML:
Change in Forced Expiratory Time and Spirometric Per-
formance During a Single Pulmonary Function Testing Ses-
sion.  Respir Care 2006, 51:246-251.
34. Tweeddale PM, Alexander F, McHardy GJR: Short term variability
in FEV1 and bronchodilator responsiveness in patients with
obstructive ventilatory defects.  Thorax 1987, 42:487-490.
35. Cochrane GM, Prieto F, Clark TJH: Intrasubject variability of
maximal expiratory flow volume curve.  Thorax 1977,
32:171-176.
36. Pennock BE, Rogers RM, McCaffree DR: Changes in measured
spirometric indices. What is significant?  Chest 1981, 80:97-99.
37. Fairshter RD, Wilson AF: Response to inhaled metaproterenol
and isoproterenol in asthmatic and normal subjects.  Chest
1980, 78:44-50.
38. Enright PL, Beck KC, Sherrill DL: Repeatability of spirometry in
18,000 adult patients.  Am J Respir Crit Care Med 2004,
169:235-238.
39. Leith DE, Mead J: Mechanisms determining residual volume of
the lungs in normal subjects.  J Appl Physiol 1967, 23:221-227.
40. Vandevoorde J, Swanney M: Is forced expiratory volume in six
seconds a valid alternative to forced vital capacity? [Letter].
Eur Respir J 2006, 28:1288-1289.